From the Department of Anesthesia, Critical Care and Pain Medicine, Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Anesthesia, First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Anesth Analg. 2020 Feb;130(2):518-524. doi: 10.1213/ANE.0000000000004273.
The incremental dose of opioids used in chronic pain management often leads to a reduced opioid analgesic effect, opioid misuse, and addiction. Central dopamine (DA) dysfunction contributes to the chronicity of pain and a decreased opioid analgesic effect. Methylphenidate (MPH/Ritalin) enhances central DA function by inhibiting DA reuptake. In this study, we used a rat model of chronic pain to examine whether combination of MPH with morphine (MOR) would improve the MOR analgesic effect under a chronic pain condition.
Tibiotarsal joint Complete Freund's Adjuvant (CFA) injection in rats was utilized to induce chronic nociception. The analgesic effect of low-dose MPH (0.25 mg/kg), low-dose MOR (2.5 mg/kg), and their combination was examined in CFA rats. Nociceptive behavior was assessed by von Frey test. Conditioned place preference (CPP) and open field tests (OFTs) were used to examine the rewarding behavior and locomotor activity in rats, respectively.
Our findings are as follows: (1) in CFA rats with chronic pain, 2.5 mg/kg of MOR had less analgesic effect than 10 mg/kg of MOR at 28 days after injury (95% confidence intervals [CIs] for difference of means of von Frey threshold in gram: -11.9 [-6.5 to -17.3]); (2) in the 1-hour time window of 30-90 minutes after injection, the combination of MPH (0.25 mg/kg) with MOR (2.5 mg/kg) increased synergistically and prolonged the analgesic effect in CFA rats as compared with MPH or MOR alone (P = .01 for MPH by MOR interaction, and 95% CIs for difference of means of von Frey threshold in gram: 3.3 [1.37-6.12] for the combination versus MPH and 3.2 [1.35-5.74] for the combination versus MOR); (3) at the low dose (0.25 mg/kg), MPH did not increase locomotor activity (MOR + MPH versus MOR, P = .13) nor significantly enhanced MOR reward behavior (MOR + MPH versus MOR, P = .63) in CFA rats.
Our data suggest that a combination therapy using low-dose MPH and MOR may produce a MOR-sparing effect in chronic pain management.
在慢性疼痛管理中,阿片类药物的增量剂量常常导致阿片类药物镇痛作用降低、阿片类药物滥用和成瘾。中枢多巴胺(DA)功能障碍导致疼痛的慢性化和阿片类药物镇痛作用降低。哌醋甲酯(MPH/利他林)通过抑制 DA 再摄取来增强中枢 DA 功能。在这项研究中,我们使用慢性疼痛大鼠模型来研究 MPH 与吗啡(MOR)联合应用是否会改善慢性疼痛状态下的 MOR 镇痛效果。
在大鼠的跖跗关节中注射完全弗氏佐剂(CFA)以诱导慢性痛觉过敏。在 CFA 大鼠中检测低剂量 MPH(0.25mg/kg)、低剂量 MOR(2.5mg/kg)及其联合应用的镇痛效果。采用von Frey 测试评估痛觉行为。条件性位置偏爱(CPP)和旷场测试(OFTs)分别用于检测大鼠的奖赏行为和运动活动。
我们的研究结果如下:(1)在慢性疼痛的 CFA 大鼠中,与损伤后 28 天时 10mg/kg 的 MOR 相比,2.5mg/kg 的 MOR 的镇痛效果较差(95%置信区间[均值差异的差值]:-11.9[-6.5 至-17.3]);(2)在注射后 30-90 分钟的 1 小时时间窗内,与单独使用 MPH 或 MOR 相比,低剂量 MPH(0.25mg/kg)与 MOR(2.5mg/kg)联合应用可协同增强并延长 CFA 大鼠的镇痛效果(MPH 与 MOR 相互作用的 P =.01,95%置信区间[均值差异的差值]:3.3[1.37-6.12]联合用药与 MPH 相比,3.2[1.35-5.74]联合用药与 MOR 相比);(3)在低剂量(0.25mg/kg)下,MPH 并未增加运动活动(MOR+MPH 与 MOR 相比,P =.13),也未显著增强 MOR 奖赏行为(MOR+MPH 与 MOR 相比,P =.63)在 CFA 大鼠中。
我们的数据表明,低剂量 MPH 和 MOR 的联合治疗可能在慢性疼痛管理中产生 MOR 节约效应。